Abiopharma

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system